FISH在乳腺癌组织HER2/neu原癌基因检测上的应用及其临床意义的研究

目的对比研究乳腺癌中免疫组化法检测c-erbB2蛋白表达和荧光免疫原位杂交法(FISH)检测HER2基因扩增,并评估其临床价值。方法免疫组化染色法及FISH法分别检测42例乳腺癌组织中c-erbB2蛋白表达及HER2基因扩增状况,并进行对比分析。结果42例乳腺癌中c-erbB2蛋白表达( )者22例(52.38%),表达( )者20例(47.62%);42例乳腺癌中有20例(47.62%)出现HER2基因扩增,22例(52.38%)无扩增。两种方法的检测结果差异无统计学意义(P>0.05);但二者的吻合度一般,(k=0.430,P<0.05)。结论免疫组化可以作为临床治疗是否应用赫赛汀(Herceptin)的初筛,免疫组化呈阳性或强阳性的病例有必要进一步进行HER2基因扩增的检测,来确定临床治疗是否应用Herceptin,指导化疗药物的选择及判断患者的预后。

Detection of HER2/neu Oncogene by Fluorescence In Situ Hybridiztion and the Clinical Significance in Breast Cancer

Objective To detect the expression of c-erbB2 protein by immunohistochemistry and HER2 gene amplification by fluorescence in situ hybridization (FISH) in breast cancer,and to evaluate their clinical significance. Methods The expression of c-erbB2 protein and HER2 gene amplification in 42 cases of breast cancer were detected by immunohistochemical staining and FISH,respectively. Results Of 42 cases,the expression of c-erbB2 protein were strongly positive in 22 cases (52.38%) and positive in 20 cases (47.62%),and HER2 gene amplification existed in 20 cases (47.62%). No significant difference was found in the results between these 2 methods,and the goodness of fit of these 2 methods was not very well (k =0.430,P <0.05). Conclusion The immunohistochemistry can be used in initial screening of whether select Herceptin in clinical therapy or not. In the cases with positive or strongly positive expression of c-erbB2,HER2 gene amplication should be detected.